NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2032

Conditions

CML, Chronic PhaseChronic Myeloid Leukemia, Chronic PhaseChronic Myeloid Leukemia, BCR/ABL-PositiveChronic Myeloid Leukemia

Interventions

DRUG

Asciminib

both arms will include asciminib treatment

DRUG

Nilotinib

in the arm B the nilotinib will be added on in all patients

Trial Locations (11)

Unknown

RECRUITING

Hospital del Mar (Barcelona), Barcelona

RECRUITING

Hospital Universitario Basurto, Bilbao

RECRUITING

Institut Català d'Oncologia Girona, Girona

RECRUITING

Hospital Virgen de las Nieves, Granada

RECRUITING

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria

RECRUITING

Hospital Gral U. Gregorio Marañón, Madrid

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

RECRUITING

Hospital Universitario La Paz, Madrid

RECRUITING

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

RECRUITING

Complejo Asistencial Universitario de Salamanca, Salamanca

RECRUITING

Hospital Universitario La Fe Valencia, Valencia

All Listed Sponsors

collaborator

Grupo Español de Leucemia Mieloide Crónica

UNKNOWN

lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER